ArticleJournal of veterinary internal medicine2026
Frequency, distribution, and prognostic impact of metastatic site in dogs with splenic hemangiosarcoma.
Article in Journal of veterinary internal medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSplenic hemangiosarcoma (SHSA) is an aggressive neoplasm of dogs characterized by high metastatic rate and short survival time. Although staging and treatment are well established prognostic factors, the implication of specific metastatic sites remains unclear. HYPOTHESIS/
objectivesDescribe the frequency and distribution of metastatic site at diagnosis in dogs with SHSA and evaluate the potential prognostic role of different metastatic locations. ANIMALS: Sixty-six dogs with histologically confirmed SHSA.
methodsRetrospective, multicenter, descriptive study of dogs with SHSA treated by splenectomy. Data collected included demographics, clinical stage, and site of metastasis at diagnosis and at death, staging procedures, histopathology results, treatment protocols, and outcome. Survival analysis was conducted using Kaplan-Meier and Cox proportional hazards models.
resultsAt diagnosis, three dogs were stage I (5%), 35 stage II (53%), and 28 stage III (42%). Overall median tumor-specific survival (TSS) was 132 days. Stage III disease and hepatic metastases were associated with significantly decreased survival (P < .001). Dogs with liver metastasis that received anthracycline-based chemotherapy had longer survival compared with dogs that received metronomic therapy (255 vs 65 days, P = .02). Muscular and pulmonary metastases did not correlate with worse outcomes. CONCLUSIONS AND CLINICAL IMPORTANCE: Stage and treatment were confirmed as prognostic factors, with patients in stage III and patients having received surgery alone having a worse prognosis. Although current staging classifies all metastatic disease as stage III, metastatic site may have variable impact on survival and should be considered when devising treatment strategy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.